# FKRP (h): 293 Lysate: sc-159806



The Power to Question

## **BACKGROUND**

Fukutin-related protein (FKRP) is ubiquitously expressed, with highest expression in heart, skeletal muscle and placenta, and weakest expression in lung, liver, brain, kidney and pancreas. FKRP localizes to the medial Golgi apparatus through its N-terminal and transmembrane domains. It is a predicted glycosyltransferase protein that plays a role in  $\alpha$ -dystroglycan glycosylation. Mutations in FKRP cause various diseases including congenital muscular dystrophy 1C (MDC1C), limb-girdle muscular dystrophy type 2I (LGMD2I) and congenital muscular dystrophies (CMDs) with brain malformations and mental retardation. FKRP mutations may also cause muscle-eye-brain disease (MEB) and Walker-Warburg syndrome (WWS), disorders characterized by disruption of brain and eye structure in addition to muscular dystrophy. Mislocalization of FKRP from the Golgi apparatus is a potential result of mutations in FKRP.

## **REFERENCES**

- 1. Brockington, M., Blake, D.J., Prandini, P., Brown, S.C., Torelli, S., Benson, M.A., Ponting, C.P., Estournet, B., Romero, N.B., Mercuri, E., Voit, T., Sewry, C.A., Guicheney, P. and Muntoni, F. 2001. Mutations in the Fukutin-related protein gene muscular dystrophy with secondary Laminin  $\alpha 2$  deficiency and abnormal glycosylation of  $\alpha$ -dystroglycan. Am. J. Hum. Genet. 69: 1198-1209.
- 2. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 606596. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- 3. Esapa, C.T., McIlhinney, R.A. and Blake, D.J. 2005. Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells. Hum. Mol. Genet. 14: 295-305.
- Müller, T., Krasnianski, M., Witthaut, R., Deschauer, M. and Zierz, S. 2005.
  Dilated cardiomyopathy may be an early sign of the C826A Fukutin-related protein mutation. Neuromuscul. Disord. 15: 372-376.
- Dolatshad, N.F., Brockington, M., Torelli, S., Skordis, L., Wever, U., Wells, D.J., Muntoni, F. and Brown, S.C. 2005. Mutated Fukutin-related protein (FKRP) localises as wildtype in differentiated muscle cells. Exp. Cell Res. 309: 370-378.
- Boito, C.A., Melacini, P., Vianello, A., Prandini, P., Gavassini, B.F., Bagattin, A., Siciliano, G., Angelini, C. and Pegoraro, E. 2005. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2l. Arch. Neurol. 62: 1894-1899.
- 7. Vajsar, J. and Schachter, H. 2006. Walker-Warburg syndrome. Orphanet J. Rare Dis. 1: 29.

## **STORAGE**

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

## **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

## **CHROMOSOMAL LOCATION**

Genetic locus: FKRP (human) mapping to 19q13.32.

#### **PRODUCT**

FKRP (h): 293 Lysate represents a lysate of human FKRP transfected 293 cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

# **APPLICATIONS**

FKRP (h): 293 Lysate is suitable as a Western Blotting positive control for human reactive FKRP antibodies. Recommended use: 10-20 µl per lane.

Control 293 Lysate: sc-110760 is available as a Western Blotting negative control lysate derived from non-transfected 293 cells.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com